Again I think they will address it once the standard is changed
The goal of the planned Phase 2b trial is to show that PharmaCyte’s therapy for pancreatic cancer can serve as a “consolidation therapy” with the first line standard of care and address the critical unmet medical need for these pancreatic cancer patients by reducing the size of their tumor with reduced side effects
Market Data 
Markets 
AI
